Clinical trials located in

København Ø

København Ø city is located in Denmark. Currently, 2 clinical trials are being conducted in this city.

  • CT-EU-00117630

    Testing of a new antibody (RO7247669) in patients with metastatic cancers

    This clinical trial is testing a new drug called RO7247669. This is a special type of antibody that targets two proteins in cancer cells, PD-1 and LAG-3. The goal is to see if this new drug can help fight advanced or metastatic solid tumors such as melanoma, lung cancer and esophageal cancer.

    In the first part of the study, researchers will administer different doses of RO7247669 to patients every 2 or 3 weeks through a drip. They will watch closely for any side effects and toxicities that may occur. Once they determine the highest safe dose, they will move on to the next section.

    In the second part, they will give the highest safe dose to more patients with a specific type of cancer. The most important thing they will look for will be how well the drug works against the tumors, such as whether they shrink for a while or stop growing. They will also monitor you for any side effects for up to 2 years.

    The aim of this study is to find the best and safest dose of this new dual-acting antibody drug and whether it will be able to effectively fight advanced solid tumors.

    • RO7247669
  • Exploring the effects of RO7204239 on Muscular Dystrophy

    The introduction of a clinical trial focused on a new treatment option for individuals with Facioscapulohumeral Muscular Dystrophy (FSHD) marks a significant step forward in medical research. The study aims to evaluate the effectiveness of RO7204239, a humanized monoclonal antibody that targets human latent myostatin, in improving the lives of those affected by FSHD.

    Participants are randomly assigned to receive either the study medication, RO7204239, or a placebo, with neither participants nor the study team aware of which treatment is being administered. The medication is given subcutaneously (under the skin) every 4 weeks.

    A crucial focus of the study is assessing the impact of RO7204239 on the muscle volume of the quadriceps femoris, the front thigh muscles, through magnetic resonance imaging (MRI) after 52 weeks of treatment. The trial also prioritizes participant safety and well-being, with close monitoring for any adverse events throughout its duration, which may extend up to 2.5 years.

    • RO7204239- new potential medication for spinal muscular atrophy

See more clinical trials in other cities in Denmark: